

**Product name:** AlloSeq Tx 17  
**Product code:** ASTX17.1(96)-A-RUO  
**Lot number:** 23-1390  
**Expiry date:** 2024-10-09  
**Number of tests:** 96  
**Storage:**

**Box 1, 3 and 4:** -15°C to -25°C  
**Box 2:** Room temperature  
**Box 5:** 2°C to 8°C

**Product Insert:** Room temperature

**Kit contents:** This product contains DNA sequencing tests designed to detect variants of the tissue typing genes for research use only.

**Warnings and Precautions** It is strongly recommended that these kits are validated by the user prior to implementation in the laboratory using samples whose genotype has been determined by other molecular based procedures. It is strongly recommended that the user follows all instructions provided via product labelling. Deviations from the described procedure are not recommended, may not be supported and could lead to typing errors. It is recommended that a positive control (human DNA) and negative/no template control (using sterile water in place of DNA) be included on every library preparation run. The positive control must produce a quantifiable library and the resultant sequence must be concordant with the sample's expected genotype. There must be no quantifiable library (measured by QuBit) in the negative template control for each experiment. If a quantifiable library is produced for the no template control the run must be repeated.

**Changes compared to the previous IFU:**

IFU083 updated: Sections 1.1, 1.4, 1.6, 1.7, 1.9 and 1.10 were edited for clarity. Section 1.3 were modified to reflect verification studies performed by CareDx. Section 6 was modified to include thermal cycler parameters requirements for compatibility with Tx assay.

The following documents, and their translations, may be downloaded from <https://www.caredx.com/lab-products/> or upon request from Manufacturer.

- IFU083\_AlloSeq Tx Instructions for Use (Version 7.0, issued Jan 2023)
- IFU083-1\_AlloSeq Tx Library Preparation Workbook RUO (Version 6.0, issued Apr 2022)
- IFU083-2\_AlloSeq Tx Hybrid Capture Workbook RUO (Version 6.0, issued Apr 2022)
- IFU083-3\_AlloSeq Tx Sequencing Workbook RUO (Version 4.0, issued Apr 2022)
- IFU083-5\_AlloSeq Tx Early Pooling Workbook RUO (Version 9.1, issued Sep 2023)
- TEC478\_AlloSeq Tx Safety Data Sheets (Version 4.2, issued Apr 2022)

**ADDRESSES:**

**Manufacturer:**

CareDx Pty Ltd,  
 20 Collie Street, Fremantle, WA, Australia, 6160.  
 Tel: +61-8-9336-4212  
 Email: [orders-aus@caredx.com](mailto:orders-aus@caredx.com)  
 Website: <http://www.caredx.com>

**Distributed by:**

CareDx AB,  
 Franzéngatan 5, SE-112 51 Stockholm, Sweden.  
 Tel: +46-8-508 939 00  
 Fax: +46-8-717 88 18  
 E-mail: [orders-se@caredx.com](mailto:orders-se@caredx.com)  
 Website: <http://www.caredx.com/>

CareDx Lab Solutions Inc.,  
 901 S. Bolmar St., Suite R, West Chester, PA 19382  
 Tel: 1-877-OLERUP1  
 Fax: 610-344-7989  
 Email: [orders-us@caredx.com](mailto:orders-us@caredx.com)  
 Website: <http://www.caredx.com>

## CERTIFICATE OF ANALYSIS

CERTIFICATE NUMBER: 23-0047

### MANUFACTURER AND TESTING LABORATORY:

CareDx Pty Ltd  
20 Collie Street  
Fremantle WA 6160  
AUSTRALIA

### PRODUCT INFORMATION

Product Name:	AlloSeq Tx 17	Kit size:	96
Batch number:	23-1390	Expiry date:	2024/10/09

### TESTING PROCEDURE

A panel of DNA samples (whose genotype was known) was used to assess the library preparation, enrichment and sequencing performance on a single kit from this batch against defined acceptance criteria

### TEST RESULTS

TEST	ACCEPTANCE CRITERIA	RESULT
<b>Pre Hybridisation</b>		
Yield	$\geq 41.36$ ng/uL	PASS
Fragment Size	$\geq 703$ bp	PASS
<b>Enrichment</b>		
Enrichment Yield	$\geq 3$ ng/uL	PASS
Fragment Size	$\geq 675$ bp	PASS
<b>Sequencing Analysis</b>		
Genotype	Correct genotypes obtained for all	PASS
Q30	$\geq 95\%$ of loci tested with $\geq 87\%$ reads with quality score of Q30 or higher	PASS
Allele balance	$\geq 95\%$ of loci tested with $\geq 38\%$ average	PASS
Coverage	$\geq 95\%$ of loci tested with $\geq 150\times$ average	PASS

### CONCLUSION

Compliance with acceptance criteria?	YES	NO
--------------------------------------	-----	----

### CERTIFICATION

I hereby certify that the testing was performed according to the company's standard operating procedures. I also certify that the results obtained were reviewed and released by myself prior to the issue of this certificate.

Signed: 

Name: *Lorie Longley*

Position: *QA Associate*

Date of Issue: *25 Oct 23*